RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 159 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $202,905 | -53.4% | 27,054 | -38.0% | 0.03% | -47.3% |
| Q1 2024 | $435,250 | +83.2% | 43,656 | +81.2% | 0.06% | +19.6% |
| Q4 2023 | $237,537 | +492.9% | 24,091 | +360.0% | 0.05% | +283.3% |
| Q3 2023 | $40,063 | +121.6% | 5,237 | +116.4% | 0.01% | +100.0% |
| Q2 2023 | $18,077 | +9.1% | 2,420 | -2.6% | 0.01% | 0.0% |
| Q1 2023 | $16,575 | +16.5% | 2,485 | +34.6% | 0.01% | 0.0% |
| Q4 2022 | $14,233 | -11.0% | 1,846 | +19.3% | 0.01% | -14.3% |
| Q3 2022 | $16,000 | – | 1,547 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Two Sigma Ventures, LP | 903,400 | $9,612,000 | 100.00% |
| Obvious Management Services, L.L.C. | 3,985,087 | $42,401,000 | 100.00% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $42,040,000 | 54.37% |
| Data Collective IV GP, LLC | 5,941,120 | $63,214,000 | 49.97% |
| MIC Capital Management UK LLP | 8,451,758 | $89,927,000 | 16.21% |
| MV Management XI, L.L.C. | 1,971,908 | $20,981,000 | 15.20% |
| ArchPoint Investors | 1,116,126 | $11,876,000 | 4.85% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $16,058,000 | 2.00% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,251,971 | $23,961,000 | 1.00% |
| Duquesne Family Office | 1,385,950 | $14,747,000 | 0.84% |